Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands.

By A. D. de Vries, N. V. van Grieken, Caspar Wn Looman, M. Casparie, E. de Vries, G. Meijer, E. Kuipers. Gastroenterology, 2008

825 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/52355487188c9358698dc825bdc96c32b0dbbe27

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Surgery

1. D. Graham
2. E. Kuipers

Citations in the corpus

• Kyoto global consensus report on Helicobacter pylori gastritis (2015, background): “79 This risk varied with the baseline stage of premalignant lesions, being 0.8%, 1.8%, 3.9% and 32.7% for patients with atrophic gastritis, intestinal metaplasia, mild-to-moderate dysplasia and severe dysplasia, respectively.”
• Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideli (2019, background): “36% person-year for any gastric neoplasia (including dysplasia and neuroendocrine tumors) [109, 114].”
• Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED) (2011, neutral): “6% for mild to moderate dysplasia, and 6% for severe dysplasia [28].”